Oleg Gladkov

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg, Ian D. Davis, Jozef Mardiak et al. · Journal of Clinical Oncology · 2010 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko et al. · The Lancet · 2021 · 799 citations

Medicine, Oncology, Pharmacology +13

HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer

Eric Van Cutsem, Yung‐Jue Bang, Feng-yi Feng et al. · Gastric Cancer · 2014 · 609 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial

Charles Butts, Mark A. Socinski, Paul Mitchell et al. · The Lancet Oncology · 2013 · 526 citations · Full text

Medicine, Oncology, Pharmacology +13

Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial

Johan Vansteenkiste, Byoung Chul Cho, Tõnu Vanakesa et al. · The Lancet Oncology · 2016 · 497 citations · Full text

Medicine, Immunology, Oncology +16